April 30th 2024
The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Immunotherapy May Be Next Frontier for AML, Says Daver
September 16th 2016Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Read More
Molecular, Genetic Studies Provide New Insights Into MDS/MPN
September 16th 2016As molecular and genetic studies have provided new insights into myelodysplastic and myeloproliferative neoplasms (MDS/MPN), diagnostic criteria and therapeutic strategies for the diseases continue to evolve.
Read More
Venetoclax/Rituximab Combo Led to Mostly Objective Responses in CLL
September 13th 2016Results from the phase Ib M13-365 study showed combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
September 8th 2016Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Read More
Ofatumumab Combination Approved by FDA for Relapsed CLL
August 31st 2016The FDA has approved ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia (CLL). The approval was based on an improvement in progression-free survival (PFS) in the phase III COMPLEMENT-2 study.
Read More
Pracinostat Receives Breakthrough Designation from FDA for Treatment of AML
August 2nd 2016Pracinostat has received a breakthrough therapy designation from the FDA, when given in combination with azacitidine, for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) aged 75 years or older, or for those who are ineligible for intensive chemotherapy, according to MEI Pharma, the company developing pracinostat.
Read More
The Role of FLT3 Inhibitors in Acute Myeloid Leukemia
July 27th 2016Raoul Tibes, MD, PhD, physician-scientist at the University Hospital Head Myeloid Malignancies, Department of Internal Medicine II at the University Hospital in Würzburg, and adjunct consultant at Mayo Clinic, discusses the role of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.
Watch
Patients with Chronic Phase CML Can Safely Conclude TKI Treatment
July 22nd 2016Patients with chronic phase chronic myeloid leukemia (CML) can safely conclude treatment of tyrosine kinase inhibitors (TKIs) following a maintained deep molecular remission, according to findings from the large EURO-SKI trial presented at the 2016 European Hematology Association (EHA) Congress.
Read More
Final Results for Phase III Trial of CPX-351 Reveal Reduced Mortality Risk in AML
July 22nd 2016Final data from a phase III trial of CPX-351 (Vyxeos) in older patients with high-risk, secondary acute myeloid leukemia (AML) revealed that CPX-351 reduced the mortality risk by 31% compared with cytarabine and daunorubicin (7+3), according to findings presented at the 2016 ASCO Annual Meeting.
Read More
INO-VATE Updated Results Confirm PFS Benefit in Relapsed/Refractory ALL
June 14th 2016The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin demonstrated significantly improved progression-free survival (PFS) and complete remission (CR) rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Nivolumab Monotherapy Achieves Positive Responses in Classical Hodgkin Lymphoma
June 7th 2016A majority of patients (66%) with classical Hodgkin lymphoma (cHL) who had progressed after receiving autologous stem cell transplant (ASCT) and brentuximab vedotin (adcetris) experienced a response to nivolumab (Opdivo) monotherapy, findings from the phase II CheckMate-205 trial showed when presented at the 2016 ASCO Annual Meeting.
Read More
Ibrutinib Patient Selection, Setting Considerations in CLL
June 4th 2016Despite the RESONATE-2 trial having demonstrated the efficacy of ibrutinib (Imbruvica) in treatment-naive elderly patients with chronic lymphocytic leukemia (CLL), Jennifer Brown, MD, explains that oncologists should carefully select patients to receive the drug depending on their age, comorbidities, and risk.
Read More
Extended RESONATE Data Illuminates Ibrutinib's Benefits in High-Risk CLL
May 16th 2016Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.
Read More
FDA Updates Ibrutinib CLL/SLL Label
May 10th 2016The FDA has updated the label for ibrutinib to include new overall survival data, an indication for the BTK inhibitor in combination with bendamustine/rituximab, and a new indication for patients with small lymphocytic lymphoma with a 17p deletion.
Read More
Blinatumomab Granted Priority Review for Pediatric ALL
May 5th 2016The FDA has granted a priority review to a supplemental biologics license application that would extend the indication for blinatumomab to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Read More